Corcept Therapeutics Incorporated (CORT)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$111.62-1.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Corcept raised 2026 revenue guidance to $950-$1,050 million. New cancer drug Lifyorli cuts death risk by 35%. The company is growing sales and expanding treatments.
Earnings missed recently and legal issues pose risks. Growth could slow if drug approvals or sales falter.
Analysts expect about 50% revenue growth. Our fair value is 45% below Street median, reflecting caution.
Breaks if: New data shows less than 20% death risk reduction
Launch and grow Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer and advance multiple oncology clinical trials.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CORT represents a speculative growth investment. The current thesis state is intact, with management focusing on revenue growth and regulatory approvals despite recent mixed signals.
The market currently assumes an expensive valuation for CORT, reflecting a premium compared to peers. There is a notable expectations gap, indicating that some investors may be cautious about the company's fragile earnings quality.
Fundamentals may show continued revenue growth, as management has raised guidance and demonstrated strong quarterly results. However, the near-term risk of missing expectations is elevated, given the high miss probability in the industry.
The thesis hinges on management's ability to meet or exceed revenue guidance and successfully advance regulatory approvals. Additionally, broader sector momentum and the performance of peer companies will be critical in shaping CORT's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports increased revenue guidance to $950 million. Analysts also raised the full-year earnings outlook significantly, reinforcing growth expectations. There are no new threats identified at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Lifyorli was FDA approved in March 2026 and over 1,300 patients started treatment by 2026-Q2. Lifyorli generated $47.6 million in revenue in 2026-Q2. Management is advancing multiple oncology trials. The trajectory shows delivering launch and early commercial growth.
“Over 1,300 patients have now started treatment with Lifyorli following FDA approval in March 2026.”
“Lifyorli approved by FDA in March 2026 for treatment of platinum-resistant ovarian cancer.”
“FDA reviewing NDA for relacorilant plus nab-paclitaxel with July 11, 2026 PDUFA date.”
Breaks if: NDA approval delayed beyond 2026 or rejected
Resubmit and work with FDA to obtain approval for relacorilant as treatment for Cushing's syndrome with expected FDA decision by December 17, 2026.
Stated as a priority in 3 of last 3 quarters. Management resubmitted the NDA in June 2026 and expects FDA decision by December 17, 2026. The company remains engaged with FDA and confident in approval. The trajectory shows ongoing regulatory progress toward approval.
“We resubmitted our New Drug Application (NDA) for relacorilant in Cushing’s syndrome in June.”
“We are engaged with the FDA to determine the best path forward for our NDA for relacorilant in Cushing’s syndrome and are confident that the ultimate outcome will be approval.”
“We are engaged with FDA to determine best path forward for our NDA for relacorilant in Cushing’s syndrome and are confident the ultimate outcome will be approval.”
Breaks if: Revenue falls below $950 million in FY26
Management has increased full-year 2026 revenue guidance reflecting growth from new product launches and expanded demand.
The outlook for CORT over the next 1 to 3 years is mixed, with strong potential but significant risks. Not investment advice.